Mutations in the RAS and BRAF genes are harmful to anti‐EGFR therapy in metastatic CRC (mCRC).4RAS and BRAF oncogene mutations are mutually exclusive and occur in 36.97% and 4.24% of CRC patients, respectively, as described in our previous work.5 Thus, identifying the unique genomic profiles and molecular phenotypes could help effectively establish the best treatment method in patients with anti‐EGFR therapy resistance. This evidence concerns the gene BRAF and colorectal carcinoma.